Compare Stocks

Date Range: 

 Aligos TherapeuticsMesoblastImmunovantScholar RockCoherus BioSciences
SymbolNASDAQ:ALGSNASDAQ:MESONASDAQ:IMVTNASDAQ:SRRKNASDAQ:CHRS
Price Information
Current Price$14.72$7.12$7.84$34.36$13.16
50-Day Moving Average$22.44$7.66$11.13$29.70$13.62
52-Week Low$12.82$6.66$7.68$10.70$12.56
52-Week High$37.51$21.28$53.75$70.00$22.22
MarketRank™
Overall Score2.21.92.02.42.2
Analysis Score3.53.14.33.53.5
Community Score5.05.05.04.14.5
Dividend Score0.00.00.00.00.0
Ownership Score2.50.80.84.22.5
Earnings & Valuation Score0.00.60.00.00.6
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$34.50$14.38$36.17$61.60$27.80
% Upside from Price Target134.38% upside101.90% upside361.31% upside79.28% upside111.25% upside
Trade Information
Market Cap$561.63 million$923.74 million$768.14 million$1.18 billion$996.90 million
BetaN/A3.40.820.10.97
Average Volume141,804389,5341,259,456282,0501,032,248
Sales & Book Value
Annual RevenueN/A$32.16 millionN/A$15.40 million$475.82 million
Price / SalesN/A28.72N/A76.792.10
CashflowN/AN/AN/AN/A$1.89 per share
Price / CashN/AN/AN/AN/A6.96
Book Value$6.01 per share$4.70 per share$4.00 per share$7.64 per share$3.90 per share
Price / BookN/A1.51N/A4.503.37
Profitability
Net Income$-108,540,000.00$-77,940,000.00$-107,430,000.00$-86,480,000.00$132.24 million
EPS($10.87)($0.74)($1.22)($2.81)$1.62
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-1,774.77%N/A-643.75%-17.23%
Return on Equity (ROE)N/A-19.82%-28.42%-60.07%-34.76%
Return on Assets (ROA)N/A-15.09%-27.03%-36.34%-9.86%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.07%N/A0.10%2.33%
Current Ratio8.71%1.72%21.79%4.55%2.40%
Quick Ratio8.71%1.72%21.79%4.55%2.20%
Ownership Information
Institutional Ownership Percentage70.84%2.02%41.06%80.08%N/A
Insider Ownership Percentage15.10%18.80%0.24%20.30%12.97%
Miscellaneous
Employees6910268119310
Shares Outstanding38.15 million129.74 million97.98 million34.42 million75.75 million
Next Earnings Date8/5/2021 (Confirmed)8/25/2021 (Estimated)8/11/2021 (Estimated)8/6/2021 (Estimated)8/5/2021 (Confirmed)
OptionableNot OptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Buy" by AnalystsCoherus BioSciences, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Buy" by Analysts
americanbankingnews.com - July 31 at 5:34 AM
Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5thCoherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th
finance.yahoo.com - July 26 at 7:03 PM
$88.85 Million in Sales Expected for Coherus BioSciences, Inc. (NASDAQ:CHRS) This Quarter$88.85 Million in Sales Expected for Coherus BioSciences, Inc. (NASDAQ:CHRS) This Quarter
americanbankingnews.com - July 24 at 4:48 AM
HC Wainwright Boosts Coherus BioSciences (NASDAQ:CHRS) Price Target to $36.00HC Wainwright Boosts Coherus BioSciences (NASDAQ:CHRS) Price Target to $36.00
americanbankingnews.com - July 23 at 8:46 AM
Coherus BioSciences (NASDAQ:CHRS) Reaches New 52-Week Low at $12.67Coherus BioSciences (NASDAQ:CHRS) Reaches New 52-Week Low at $12.67
americanbankingnews.com - July 22 at 5:18 PM
 Brokerages Anticipate Coherus BioSciences, Inc. (NASDAQ:CHRS) to Announce -$0.18 EPS Brokerages Anticipate Coherus BioSciences, Inc. (NASDAQ:CHRS) to Announce -$0.18 EPS
americanbankingnews.com - July 22 at 1:14 AM
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory BoardCoherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board
finance.yahoo.com - July 21 at 12:39 PM
Coherus BioSciences, Inc. Common Stock (CHRS)Coherus BioSciences, Inc. Common Stock (CHRS)
nasdaq.com - July 20 at 8:00 PM
Coherus BioSciences (NASDAQ:CHRS) Reaches New 52-Week Low at $12.90Coherus BioSciences (NASDAQ:CHRS) Reaches New 52-Week Low at $12.90
americanbankingnews.com - July 15 at 6:10 PM
Coherus BioSciences (NASDAQ:CHRS) Shareholders Are Down 43% On Their SharesCoherus BioSciences' (NASDAQ:CHRS) Shareholders Are Down 43% On Their Shares
nasdaq.com - July 11 at 12:47 PM
How Is The Coherus BioSciences Inc. (NASDAQ: CHRS) Performance Outlook For The Coming Months?How Is The Coherus BioSciences Inc. (NASDAQ: CHRS) Performance Outlook For The Coming Months?
marketingsentinel.com - July 5 at 1:49 PM
Coherus BioSciences Inc. (NASDAQ:CHRS) Is 8.83% Above Its 52-Week Low, But How Long Will It Remain So?Coherus BioSciences Inc. (NASDAQ:CHRS) Is 8.83% Above Its 52-Week Low, But How Long Will It Remain So?
marketingsentinel.com - June 19 at 12:32 PM
Mizuho Securities Stick to Their Buy Rating for Coherus BiosciencesMizuho Securities Stick to Their Buy Rating for Coherus Biosciences
investing.com - June 9 at 12:42 PM
Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 HighlightsCoherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights
finance.yahoo.com - June 4 at 7:25 PM
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study PactThe Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
msn.com - June 4 at 2:25 PM
Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer TrialCoherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial
finance.yahoo.com - June 4 at 2:25 PM
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
finance.yahoo.com - June 3 at 6:35 PM
2 “Strong Buy” Stocks Trading at a Bargain Right Now2 “Strong Buy” Stocks Trading at a Bargain Right Now
finance.yahoo.com - May 25 at 9:53 PM
Coherus BioSciences Inc. [CHRS] Stock trading around $14.14 per share: What’s Next?Coherus BioSciences Inc. [CHRS] Stock trading around $14.14 per share: What’s Next?
dbtnews.com - May 18 at 5:55 PM
We Think Some Shareholders May Hesitate To Increase Coherus BioSciences, Inc.s (NASDAQ:CHRS) CEO CompensationWe Think Some Shareholders May Hesitate To Increase Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation
finance.yahoo.com - May 15 at 10:58 AM
Coherus BioSciences Inc (CHRS)Coherus BioSciences Inc (CHRS)
investing.com - May 14 at 10:35 PM
Coherus BioSciences to Present at the Bank of America Health Care ConferenceCoherus BioSciences to Present at the Bank of America Health Care Conference
finance.yahoo.com - May 7 at 5:57 PM
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline ProgressCoherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
markets.businessinsider.com - May 7 at 2:56 AM
Coherus BioSciences Inc (CHRS) Q1 2021 Earnings Call TranscriptCoherus BioSciences Inc (CHRS) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 7 at 2:56 AM
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue EstimatesCoherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 6 at 9:56 PM
DateCompanyBrokerageAction
8/2/2021ImmunovantCredit Suisse Group
Downgrade
7/23/2021Coherus BioSciencesHC Wainwright
Boost Price Target
7/7/2021ImmunovantChardan Capital
Reiterated Rating
7/1/2021ImmunovantChardan Capital
Reiterated Rating
6/2/2021ImmunovantCredit Suisse Group
Boost Price Target
6/2/2021ImmunovantSVB Leerink
Lower Price Target
6/2/2021ImmunovantRobert W. Baird
Lower Price Target
6/2/2021ImmunovantHC Wainwright
Lower Price Target
6/1/2021ImmunovantRaymond James
Downgrade
6/1/2021ImmunovantGuggenheim
Downgrade
6/1/2021ImmunovantStifel Nicolaus
Downgrade
5/17/2021Aligos TherapeuticsPiper Sandler
Initiated Coverage
5/17/2021Coherus BioSciencesBarclays
Lower Price Target
5/13/2021Coherus BioSciencesHC Wainwright
Lower Price Target
5/10/2021ImmunovantHC Wainwright
Lower Price Target
5/7/2021Coherus BioSciencesMaxim Group
Initiated Coverage
5/7/2021Coherus BioSciencesHC Wainwright
Lower Price Target
4/13/2021MesoblastMaxim Group
Upgrade
4/7/2021MesoblastMaxim Group
Upgrade
4/1/2021Aligos TherapeuticsJefferies Financial Group
Reiterated Rating
3/24/2021Aligos TherapeuticsPiper Sandler
Boost Price Target
2/25/2021Coherus BioSciencesCitigroup
Lower Price Target
2/25/2021Coherus BioSciencesHC Wainwright
Lower Price Target
2/16/2021ImmunovantStifel Nicolaus
Reiterated Rating
2/3/2021ImmunovantRaymond James
Lower Price Target
2/3/2021ImmunovantSVB Leerink
Lower Price Target
2/3/2021ImmunovantHC Wainwright
Lower Price Target
2/2/2021ImmunovantCredit Suisse Group
Downgrade
2/2/2021ImmunovantStifel Nicolaus
Lower Price Target
1/25/2021Scholar RockBMO Capital Markets
Boost Price Target
1/21/2021Scholar RockWedbush
Boost Price Target
1/19/2021MesoblastJefferies Financial Group
Downgrade
1/13/2021ImmunovantHC Wainwright
Reiterated Rating
1/11/2021Scholar RockCredit Suisse Group
Initiated Coverage
1/6/2021Scholar RockJPMorgan Chase & Co.
Initiated Coverage
12/22/2020MesoblastMaxim Group
Downgrade
12/15/2020MesoblastHC Wainwright
Reiterated Rating
12/4/2020MesoblastChardan Capital
Downgrade
11/20/2020MesoblastHC Wainwright
Boost Price Target
11/19/2020Coherus BioSciencesMizuho
Lower Price Target
11/13/2020ImmunovantTruist
Boost Price Target
11/13/2020ImmunovantRobert W. Baird
Boost Price Target
11/13/2020ImmunovantHC Wainwright
Boost Price Target
11/13/2020ImmunovantSVB Leerink
Boost Price Target
11/12/2020ImmunovantChardan Capital
Boost Price Target
11/10/2020Aligos TherapeuticsJefferies Financial Group
Initiated Coverage
11/10/2020Aligos TherapeuticsJPMorgan Chase & Co.
Initiated Coverage
11/10/2020Aligos TherapeuticsPiper Sandler
Initiated Coverage
11/10/2020Aligos TherapeuticsCantor Fitzgerald
Initiated Coverage
11/10/2020Scholar RockWedbush
Boost Price Target
11/6/2020Coherus BioSciencesHC Wainwright
Lower Price Target
10/28/2020ImmunovantUBS Group
Initiated Coverage
10/28/2020Scholar RockBMO Capital Markets
Boost Price Target
10/27/2020Scholar RockRobert W. Baird
Reiterated Rating
10/22/2020MesoblastRoyal Bank of Canada
Initiated Coverage
10/12/2020ImmunovantGuggenheim
Initiated Coverage
10/5/2020MesoblastMaxim Group
Lower Price Target
10/2/2020MesoblastHC Wainwright
Lower Price Target
8/14/2020MesoblastMaxim Group
Boost Price Target
8/7/2020Coherus BioSciencesMaxim Group
Initiated Coverage
8/7/2020Coherus BioSciencesHC Wainwright
Boost Price Target
7/16/2020Coherus BioSciencesBank of America
Initiated Coverage
6/29/2020Scholar RockBMO Capital Markets
Reiterated Rating
5/29/2020MesoblastMaxim Group
Initiated Coverage
5/28/2020MesoblastLADENBURG THALM/SH SH
Boost Price Target
5/28/2020MesoblastHC Wainwright
Reiterated Rating
5/9/2020Coherus BioSciencesMaxim Group
Initiated Coverage
5/8/2020Coherus BioSciencesHC Wainwright
Reiterated Rating
4/27/2020MesoblastHC Wainwright
Reiterated Rating
4/17/2020Coherus BioSciencesSunTrust Banks
Initiated Coverage
4/9/2020MesoblastHC Wainwright
Reiterated Rating
3/11/2020Scholar RockRobert W. Baird
Initiated Coverage
3/5/2020Coherus BioSciencesCredit Suisse Group
Reiterated Rating
2/29/2020Coherus BioSciencesMaxim Group
Reiterated Rating
2/28/2020MesoblastMaxim Group
Reiterated Rating
2/28/2020Coherus BioSciencesHC Wainwright
Boost Price Target
2/6/2020MesoblastHC Wainwright
Reiterated Rating
2/6/2020Coherus BioSciencesJPMorgan Chase & Co.
Boost Price Target
2/4/2020Coherus BioSciencesMizuho
Reiterated Rating
12/19/2019MesoblastDawson James
Initiated Coverage
11/27/2019MesoblastMaxim Group
Reiterated Rating
11/27/2019Coherus BioSciencesMizuho
Initiated Coverage
11/26/2019MesoblastHC Wainwright
Reiterated Rating
11/25/2019Coherus BioSciencesHC Wainwright
Reiterated Rating
11/19/2019Scholar RockCowen
Reiterated Rating
11/8/2019Coherus BioSciencesCredit Suisse Group
Reiterated Rating
10/22/2019MesoblastCantor Fitzgerald
Reiterated Rating
9/29/2019Coherus BioSciencesMizuho
Set Price Target
9/12/2019MesoblastMaxim Group
Reiterated Rating
9/10/2019MesoblastCantor Fitzgerald
Set Price Target
9/10/2019MesoblastOppenheimer
Set Price Target
8/13/2019Coherus BioSciencesMizuho
Initiated Coverage
5/15/2019Scholar RockWedbush
Reiterated Rating
2/27/2019Scholar RockCowen
Reiterated Rating
11/12/2018Scholar RockCowen
Reiterated Rating
11/9/2018Scholar RockWedbush
Reiterated Rating
(Data available from 8/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.